Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
TAKEDA NEW ZEALAND LIMITED,Brentuximab vedotin,Previously untreated systemic anaplastic large-cell lymphoma (sALCL),Brentuximab vedotin (ADCETRISÂ®),Options for investment,Hospital,Oncology Agents and Immunosuppressants
